GlassScriptPhysician profile
Weston E Spencer
NPI 1649295809
$2,083.29
in general payments reported to CMS, 2019-2025
20 companies · $274 in 2025
The $274 reported for 2025 was more than what 82% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $148 · 2020: $155 · 2021: $238 · 2022: $279 · 2023: $116 · 2024: $874 · 2025: $274.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,264.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,263.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $688.77 | 2021-2025 | Qelbree |
| Tris Pharma INC | $281.73 | 2019-2025 | Onyda Xr, Dyanavel Xr |
| Corium, LLC | $178.92 | 2022-2025 | Azstarys |
| Astrazeneca Pharmaceuticals LP | $117.31 | 2022-2025 | Breztri |
| Ironshore Pharmaceuticals INC. | $116.58 | 2021-2024 | |
| Cranial Technologies, INC | $105.01 | 2019-2025 | Doc Band |
| Merck Sharp & Dohme LLC | $95.80 | 2021-2024 | Vaxneuvance, Gardasil 9, Gardasil |
| Pfizer INC. | $94.19 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $74.51 | 2023-2025 | |
| Acadia Pharmaceuticals INC | $58.55 | 2024 | Daybue |
| Sobi, INC | $51.23 | 2019-2022 | |
| Adlon Therapeutics L.P. | $42.44 | 2020-2021 | |
| Quidel Corporation | $40.81 | 2021 | |
| Seqirus USA INC | $34.24 | 2022-2025 | Flucelvax |
| Rhythm Pharmaceuticals, INC. | $22.17 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $20.94 | 2025 | Jornay Pm |
| Biomarin Pharmaceutical INC. | $17.72 | 2024 | Voxzogo 1.2mg |
| Shire North American Group INC | $16.69 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.96 | 2020 | |
| Ultragenyx Pharmaceutical INC. | $11.72 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Weston Spencer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.